Public health nurse impact

Public health nurse impact Committed to public health, passionate about improving lives and community health through health education, disease prevention and community outreach.
(13)

Advocating for equitable health care for all. Dedicated to making a difference, one life at a time.

20/06/2025

Documentation
Motivation
Logistics cycle

20/06/2025
20/06/2025

Some of you this ka song is older than you 😅

Child health week is here. Take your children and make sure they receive the required vaccines.
20/06/2025

Child health week is here. Take your children and make sure they receive the required vaccines.

𝐌𝐚𝐫𝐤 𝐲𝐨𝐮𝐫 𝐜𝐚𝐥𝐞𝐧𝐝𝐚𝐫!

𝑪𝒉𝒊𝒍𝒅 𝑯𝒆𝒂𝒍𝒕𝒉 𝑾𝒆𝒆𝒌 𝒊𝒔 𝒉𝒆𝒓𝒆 23 𝒕𝒐 28 𝑱𝒖𝒏𝒆 2025!

Take your under-5 child to the nearest health facility or outreach site to get vaccinated, dewormed, and receive vitamin A.

19/06/2025

Ma occupational diseases ago 😅😅😅🤭

19/06/2025

Family pillar answer for yourself

19/06/2025

Occupational asthma
Health trends
Rabies

19/06/2025

FDA approves twice-a-year injection for HIV prevention

(CNN) A drug currently used to treat certain HIV infections has received approval from the US Food and Drug Administration to be used to prevent HIV.

Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo.

In clinical trials, the drug was found to dramatically reduce the risk of infection and provide near-total protection against HIV, significantly more than the primary options available for pre-exposure prophylaxis or PrEP.

Therapies called PrEP have been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting shots, such as injections every two months of the medication Apretude.

But a twice-yearly shot of lenacapavir has now become another option in the prevention toolbox – making it the first and only such shot for HIV prevention.

“Yeztugo could be the transformative PrEP option we’ve been waiting for – offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,” Dr. Carlos del Rio, a distinguished professor of medicine in the Division of Infectious Diseases at Emory University School of Medicine and co-director of the Emory Center for AIDS Research, said in a Gilead news release.

“A twice-yearly injection could greatly address key barriers like adherence and stigma, which individuals on more frequent PrEP dosing regimens, especially daily oral PrEP, can face. We also know that, in research, many people who need or want PrEP preferred less frequent dosing.”

With any PrEP drug, “by having that medicine in your bloodstream or in your body, if you encounter HIV, it blocks it from taking hold. It arrests infection from taking hold,” said Dr. Jared Baeten, senior vice president of clinical development and the virology therapeutic area head at Gilead Sciences.

The human immunodeficiency virus or HIV, spread primarily through unprotected s*x or sharing needles, attacks the body’s immune system, and without treatment, it can lead to acquired immunodeficiency syndrome or AIDS.

19/06/2025

FDA approves twice-a-year injection for H.I.V prevention

19/06/2025

All the best today
Don't be electrocuted
🤭

18/06/2025

Sampling
Disease surveillance
Disease outbreak investigation

18/06/2025

Applications were closed yesterday

Address

Lusaka

Website

Alerts

Be the first to know and let us send you an email when Public health nurse impact posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share